Table 4 Summary of the key features of “real-world” evidence pertaining to fedratinib treatment in MF.
Setting | Number of patients | Age (median, years) | Duration of ruxolitinib treatment prior to fedratinib treatment (months) | Spleen response | Symptom response (%) | Duration of fedratinib treatment (median, months) | Reference |
|---|---|---|---|---|---|---|---|
Multicenter Mayo Clinics, USA | 28 | 73 | 18 | 13% of patientsa | 33 | 7.8 | [15] |
Community oncology clinics, USA | 150 | 68 (mean) | 7.6 | 55% mean reduction in size overallb | >50% reduction overall | 4.4 | [16] |
Integra Connect PrecisionQ claims database, USA | 30 | 75 | NR | NR | NR | 11 | [17] |
Flatiron Health national claims database, USA | 70 | 71 | 25.3 | NR | NR | 3.7 | [18] |
Multicenter, Europe | 150 | 68.7 | NR | 66.8%b | 42%-complete response | 14.3 | [19] |
MAP, Israel | 16 | 77 | 17 | 17% mean reduction in size overallb | 43% of patients had some reduction in symptoms | 6 | [20] |
